New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 18, 2014
07:40 EDTSHPG, VRX, AGNAllergan likely to bid for Shire, says SunTrust
SunTrust believes that Allergan (AGN) will soon bid for Shire (SHPG), and the firm thinks that this scenario is more attractive for Allergan shareholders than the offer from Valeant (VRX), as ia Shrie acquisition wouldremove the risk of holding Valeant shares. A combination of Allergan and Shire would have several advantages, including sustainable low double digit revenue growth, a more diversified sales mix, and a preservation of high value R&D programs, according to the firm. It thinks the deal would be 50% accretive to EPS in the first year and enable five year EPS CAGR to accelerate meaningfully. The firm keeps a $200 price target and Buy rating on Allergan.
News For AGN;VRX;SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
August 21, 2015
09:38 EDTSHPGUBS global healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
August 20, 2015
18:09 EDTVRXValeant a bargain, poised for growth, Barron's says
Subscribe for More Information
16:48 EDTVRXOn The Fly: Top stock stories for Thursday
Subscribe for More Information
13:26 EDTVRXOn The Fly: Top stock stories at midday
Subscribe for More Information
09:20 EDTVRXOn The Fly: Pre-market Movers
Subscribe for More Information
09:13 EDTVRXPalatin up 15.18% after Valeant announces plans to buy Sprout for $1B
Subscribe for More Information
08:16 EDTAGNAllergan's Botox resubmission for lower limb spasticiy accepted by FDA
Allergan 's resubmission of its Supplemental Biologics License Application for Botox for the treatment of adults with lower limb spasticity in adults has been accepted by the FDA. A six-month review period has been assigned for the sBLA. The Prescription Drug User Fee Act date is expected to be in 1Q16. The resubmission provides additional data from a double-blind, placebo controlled study involving 468 patients with lower limb spasticity. The FDA also approved an increase to the maximum Botox cumulative dose within three months from 360 to 400 units in adults treated for one or more indications.
07:31 EDTVRXValeant to acquire Sprout Pharma for $1B, plus a share of future profits
Subscribe for More Information
05:50 EDTVRXValeant nears deal to buy Sprout Pharma for $1B, WSJ reports
Subscribe for More Information
August 17, 2015
06:55 EDTSHPGBaxalta initiated with an Outperform at William Blair
Subscribe for More Information
06:48 EDTSHPGShire to raise Baxalta offer if given access to company's books, Telegraph says
Subscribe for More Information
August 16, 2015
18:01 EDTVRXSenators question Valeant, Hospira on 'artifically inflated' drug prices
Subscribe for More Information
15:03 EDTSHPGShire must raise bid to $35B to interest Baxalta, Sunday Times says
Shire (SHPG) will have to increase its bid for Baxalta (BXLT) by about $5B to $35B in order to entice the company's board, reports the Sunday Times, citing people working on the deal. Even a $35B deal would only be a starting point, cautioned the sources. Reference Link
August 14, 2015
17:32 EDTAGNPershing Square gives quarterly update on stakes, liquidates Allergan position
Subscribe for More Information
17:08 EDTVRX, AGN, SHPGPaulson & Co gives quarterly update on stakes
Subscribe for More Information
15:33 EDTAGNEndo confirms court ruling upholding OPANA ER intellectual property
Subscribe for More Information
14:15 EDTAGNEndo successful in blocking Opana generic until 2023, Bloomberg reports
Subscribe for More Information
08:35 EDTVRXHayman takes Mylan, Perrigo stakes, boasts exposure to energy
Subscribe for More Information
07:37 EDTAGNJANA reports new stakes in Allergan, TWC, sells Applied Materials
Subscribe for More Information
07:15 EDTSHPGShire eyes more details of Baxalta sales outlook, Bloomberg reports
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use